Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral oxytocin plus ESDM in young children with autism
ChiCTR2500099534Phase 2Not yet recruiting
- Sponsor
- University of Electronic Science and Technology of China
- Start
- Mar 2025
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of oxytocin in Autism Spectrum Disorder (ASD) (3 arms), sponsored by University of Electronic Science and Technology of China. Primary endpoints: Autism Diagnostic Observation Schedule - 2 (ADOS-2) score and Social Responsivity Scale-2 (SRS-2) score. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
oxytocin
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on ChiCTR2500099534.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500099534.